Obermatt
See Similar Stocks →

Basilea Pharmaceutica

SWX:BSLN · CH0011432447
BiotechnologySmall

360

66
Profit price6
Owner Earnings Yield93
Dividend Yield1
Price/Sales76
EV / Gross Profit53
Price/Book35
Return on Capital92
Cash Return on Capital98
Return on Equity96
EBIT Margin80
Gross Profitability65
Accruals39
Owner Earnings Margin96
Sales growth53
Profit Growth84
Long-Term EPS Growth30
Reinvestment4
Price momentum51
Debt load37
Refinancing82
Debt Payback100
Liquidity85
Analyst ratings30
Opinion Changes50
Price Target Upside36
Market mood31
Value Creation12/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Basilea Pharmaceutica clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountrySwitzerland
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeSWX
Founded2010
Employees193
Websitebasilea.com
ISINCH0011432447
Last UpdateApr 2, 2026
Indices
SPI (Switzerland)
Themes
DermatologyInfectious DiseasesBiotechnologyCommercialPharmaceutical

Description

Basilea Pharmaceutica AG, an independent biopharmaceutical company, engages in the development of anti-bacterial and anti-fungal agents to fight drug resistance, as well as on dermatology drugs. Through its subsidiary Jiangsu Innovative New Drug Rese…

Analysis

Quality compounder

Basilea Pharmaceutica AG earns the quality_compounder label: good underlying economics priced fairly, with no obvious bargain or excess.

On valuation, the picture is fair. The owner-earnings multiple stands at 15.6×; owner earnings: the cash an owner could take out each year.

Growth is moderate; the safety picture is adequate. The company scores 12/20 on our value-creation score: creating some value. Analyst sentiment is cautious.

Flags to be aware of: Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
53
2026

All-time high

73

Mar 2026

All-time low

50

Feb 2026

Average rank

59

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
76
—
—
—
Price/Earnings
27
—
—
—
Price/Book
35
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
37
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Basilea Pharmaceutica with its peers
ABIVAX
PAR:ABVX
26
CountryFrance
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Immatics
NAQ:IMTX
31
CountryGermany
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Transgene
PAR:TNG
15
CountryFrance
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Kuros Biosciences
SWX:KURN
80
CountrySwitzerland
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
OKYO Pharma
NAQ:OKYO
40
CountryUK
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Genfit
PAR:GNFT
32
CountryFrance
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →